“This study’s findings—that adding antiandrogen therapy to the radiation typically used against recurrence reduces the incidence of metastasis, death from prostate cancer and overall deaths—will change the standard of care for patients experiencing a postoperative recurrence,” Dr Shipley added.
Read Now
Stay up to date with urology news & updates by subscribing to receive the free UPM print publications or e‑Newsletters.